Mosaic ImmunoEngineering (OTCMKTS:CPMV) Posts Quarterly Earnings Results

Mosaic ImmunoEngineering (OTCMKTS:CPMVGet Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.02) earnings per share for the quarter, Zacks reports.

Mosaic ImmunoEngineering Price Performance

Shares of Mosaic ImmunoEngineering stock remained flat at $0.63 during trading on Tuesday. The company had a trading volume of 6 shares, compared to its average volume of 1,068. The stock has a market cap of $4.54 million, a PE ratio of -4.18 and a beta of 0.15. The stock has a 50-day simple moving average of $0.85 and a 200-day simple moving average of $0.88. Mosaic ImmunoEngineering has a 12 month low of $0.10 and a 12 month high of $1.13.

About Mosaic ImmunoEngineering

(Get Free Report)

Mosaic ImmunoEngineering, Inc, a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.

Featured Stories

Earnings History for Mosaic ImmunoEngineering (OTCMKTS:CPMV)

Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.